ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative Employers
  Post Job | Search Resumes | Login

 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Print   Email 

FDA, Merck & Co., Inc. (MRK) Warn Against Using Victrelis With Some HIV Drugs


2/10/2012 7:35:59 AM

The U.S. Food and Drug Administration said Thursday the use of Merck & Co.'s (MRK) Hepatitis C drug Victrelis with certain types of HIV medicines may reduce effectiveness of both types of treatments. Victrelis was approved last year to treat Hepatitis C, a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. Although Victrelis wasn't approved for use in people who are infected with both HIV, another virus transmitted through contaminated blood, and Hepatitis C, many patients have both diseases. FDA's announcement was prompted by the results of a small study conducted by Merck that specifically looked at the concentrations, or blood levels, of Victrelis when used with three so-called ritonavir-boosted HIV drugs. Treatments for both Hepatitis C and HIV include several drugs meant to be administered together.

Read at Wall Street Journal
Read at Fox News
Read at News Release
Read at Zee News
Read at News Release
 
 Read Article at  Related Companies  News Categories
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES